LTF Human Pre-designed siRNA Set A contains three designed siRNAs for LTF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LTGO-33 is a potent and selective voltage-gated sodium channel NaV1.8 inhibitor. LTGO-33 inhibits NaV1.8 in the nM potency range and exhibits over 600-fold selectivity against human NaV1.1-NaV1.7 and NaV1.9. LTGO-33 exhibits state-independent inhibition with similar potencies on channels in the closed and inactivated conformations. LTGO-33 inhibits native TTX-R NaV1.8 currents in non-human primate and human […]

LTGO-33 is a potent and selective voltage-gated sodium channel NaV1.8 inhibitor. LTGO-33 inhibits NaV1.8 in the nM potency range and exhibits over 600-fold selectivity against human NaV1.1-NaV1.7 and NaV1.9. LTGO-33 exhibits state-independent inhibition with similar potencies on channels in the closed and inactivated conformations. LTGO-33 inhibits native TTX-R NaV1.8 currents in non-human primate and human […]

LTGO-33 is a potent and selective voltage-gated sodium channel NaV1.8 inhibitor. LTGO-33 inhibits NaV1.8 in the nM potency range and exhibits over 600-fold selectivity against human NaV1.1-NaV1.7 and NaV1.9. LTGO-33 exhibits state-independent inhibition with similar potencies on channels in the closed and inactivated conformations. LTGO-33 inhibits native TTX-R NaV1.8 currents in non-human primate and human […]

LTGO-33 is a potent and selective voltage-gated sodium channel NaV1.8 inhibitor. LTGO-33 inhibits NaV1.8 in the nM potency range and exhibits over 600-fold selectivity against human NaV1.1-NaV1.7 and NaV1.9. LTGO-33 exhibits state-independent inhibition with similar potencies on channels in the closed and inactivated conformations. LTGO-33 inhibits native TTX-R NaV1.8 currents in non-human primate and human […]

LTK Human Pre-designed siRNA Set A contains three designed siRNAs for LTK gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LTN1 Human Pre-designed siRNA Set A contains three designed siRNAs for LTN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LTO1 Human Pre-designed siRNA Set A contains three designed siRNAs for LTO1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LTV1 Human Pre-designed siRNA Set A contains three designed siRNAs for LTV1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LUC7L Human Pre-designed siRNA Set A contains three designed siRNAs for LUC7L gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LUC7L2 Human Pre-designed siRNA Set A contains three designed siRNAs for LUC7L2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LUC7L3 Human Pre-designed siRNA Set A contains three designed siRNAs for LUC7L3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LUM Human Pre-designed siRNA Set A contains three designed siRNAs for LUM gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Luotonin F is an alkaloid found in the aerial parts of the P. nigellastrum Bunge. Luotonin F shows cytotoxic activity against mouse leukemia P-388 cells by inhibiting human topoisomerase II[1][2].

CFI-402257 hydrochloride is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 hydrochloride has anti-cancer activity[1].

CFI-402257 hydrochloride is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 hydrochloride has anti-cancer activity[1].

CFI-402257 hydrochloride is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 hydrochloride has anti-cancer activity[1].

CFI-402257 hydrochloride is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 hydrochloride has anti-cancer activity[1].

CFI-402257 hydrochloride is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 hydrochloride has anti-cancer activity[1].

Luzopeptin A (BBM-928 A) is an actinoleukin-like antitumor antibiotic. Luzopeptin A is a bifunctional DNA intercalator which can interact with isolated DNA molecules. Luzopeptin A induces an unwinding-rewinding process of the closed superhelical PM2 DNA. Luzopeptin A is active against HIV-1 and HIV-2 reverse transcriptase with IC50s of 7 nM and 68 nM for HIV-1 […]

LUZP1 Human Pre-designed siRNA Set A contains three designed siRNAs for LUZP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LUZP2 Human Pre-designed siRNA Set A contains three designed siRNAs for LUZP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LVRN Human Pre-designed siRNA Set A contains three designed siRNAs for LVRN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LXJ-02 is a potent inhibitor of EDPs/EBP peptide–protein interaction, with the KD of 117 μM for EDPs. LXJ-02 activates the macrophage-MMP-12 axis to increase MMP-12 expression and degrade ECM components like elastin[1].

LXN Human Pre-designed siRNA Set A contains three designed siRNAs for LXN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LXQ-217 is an oral active SHP2 inhibitor with the IC50 of 2.01 μM. LXQ-217 induces apoptosis and inhibits cell growth in vivo and in vitro[1].

LY117018 TFA, a Raloxifene analog, is a selective estrogen receptor modulator. LY117018 TFA exerts antiproliferative effects on breast cancer cell lines[1][2][3].

LY117018 TFA, a Raloxifene analog, is a selective estrogen receptor modulator. LY117018 TFA exerts antiproliferative effects on breast cancer cell lines[1][2][3].

LY117018 TFA, a Raloxifene analog, is a selective estrogen receptor modulator. LY117018 TFA exerts antiproliferative effects on breast cancer cell lines[1][2][3].

LY334370 hydrochloride is a selective 5-HT1F receptor agonist with a Kd value of 0.446 nM. LY334370 hydrochlorid has anti-migraine activity[1][2].

LY382884 is a selective antagonist for GluR5 kainate receptor. LY382884 prevents the induction of NMDA receptor independent long-term potentiation (LTP)[1].

LY6D Human Pre-designed siRNA Set A contains three designed siRNAs for LY6D gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LY6E Human Pre-designed siRNA Set A contains three designed siRNAs for LY6E gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LY6G6C Human Pre-designed siRNA Set A contains three designed siRNAs for LY6G6C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LY6G6D Human Pre-designed siRNA Set A contains three designed siRNAs for LY6G6D gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LY6G6F Human Pre-designed siRNA Set A contains three designed siRNAs for LY6G6F gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LY6H Human Pre-designed siRNA Set A contains three designed siRNAs for LY6H gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LY6K Human Pre-designed siRNA Set A contains three designed siRNAs for LY6K gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LY6L Human Pre-designed siRNA Set A contains three designed siRNAs for LY6L gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LY6S Human Pre-designed siRNA Set A contains three designed siRNAs for LY6S gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LY75 Human Pre-designed siRNA Set A contains three designed siRNAs for LY75 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LY86 Human Pre-designed siRNA Set A contains three designed siRNAs for LY86 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LY9 Human Pre-designed siRNA Set A contains three designed siRNAs for LY9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LY96 Human Pre-designed siRNA Set A contains three designed siRNAs for LY96 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LYAR Human Pre-designed siRNA Set A contains three designed siRNAs for LYAR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LYG1 Human Pre-designed siRNA Set A contains three designed siRNAs for LYG1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.